- Home
- Automated
- List of product information
- NUROFEN EXPRESS LIQUID CAPSULE 400MG [SIN14561P]
NUROFEN EXPRESS LIQUID CAPSULE 400MG [SIN14561P]
Active ingredients: NUROFEN EXPRESS LIQUID CAPSULE 400MG
Last updated 26 October 2025
On this page
Product Info
NUROFEN EXPRESS LIQUID CAPSULE 400MG
[SIN14561P]
Product information
Active Ingredient and Strength | IBUPROFEN - 400 MG |
Dosage Form | CAPSULE, LIQUID FILLED |
Manufacturer and Country | PATHEON SOFTGELS B.V - NETHERLANDS |
Registration Number | SIN14561P |
Licence Holder | RECKITT BENCKISER (SINGAPORE) PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | M01AE01 |
Indications
Nurofen Express Liquid Capsules are indicated for the relief of pain such as headache, dental pain, period pain, rheumatic pain, muscular pain and backache. Nurofen Express Liquid Capsules also relieve fever such as fever associated with cold & flu.
Table caption
Recommended Dosage | Adults and children over 12 years | |
For oral use and short-term use only. | Single dose: | 1–2 liquid capsule of 200mg respectively. |
If necessary, take additional doses of 1 or 2 capsules (200mg ibuprofen) or 1 capsule (400mg ibuprofen) but do not exceed a total dose of 1200mg ibuprofen in any 24-hour period. The dosing interval should not be below 4 hours for the 200mg dose and not below 6 hours for the 400mg dose.
If this product is required for more than 3 days, or if the symptoms worsen, the patient is advised to consult a doctor.
It is recommended that patients with sensitive stomachs take Nurofen Express Liquid Capsules with food.
If taken shortly after eating, the onset of action of Nurofen Express Liquid Capsules may be delayed. If this happens, do not take more Nurofen Express Liquid Capsules than recommended or until the correct re-dosing interval has passed.
Contraindications
Hypersensitivity to ibuprofen, ponceau 4R (E124) or to any of the excipients
In patients with a history of hypersensitivity reactions (e.g. bronchospasm, asthma, rhinitis, angioedema or urticaria) associated with the intake of acetylsalicylic acid (ASA) or other non-steroidal anti-inflammatory drugs (NSAIDs)
Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding)
History of gastrointestinal bleeding or perforation related to previous NSAIDs therapy
Patients with severe hepatic failure, severe renal failure, coronary heart disease or severe heart failure (see also section Warnings and Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)
In patients with cerebrovascular or other active bleeding
In patients with bleeding diathesis or coagulation disorders
In patients with unclarified blood-formation disturbances
In patients with severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake)
In patients who have recently undergone coronary artery bypass graft (CABG) surgery and re-vascularization procedures
The last trimester of pregnancy (see section Pregnancy and Lactation – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)
Adolescents weighing less than 40 kg or children under 12 years of age